Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
In overweight patients and those with obesity provided with GLP-1RAs, there was a significant reduction in CRC risk when compared with insulin (HR, 0.50
Tirzepatide works by targeting the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, making it the first weight loss and diabetes care medication that targets 2 receptor agonists
Oral GLP-1 medications reduce some barriers associated with injectable administration particularly convenience and needle aversion and may broaden uptake among patients who previously declined injectable therapy
Among 11 meta-analyses, 3 did not report primary studies
US$ 21.78
US$ 24.76
US$ 21.10
